Niagen Bioscience Sees Moderate Gain as It Launches New Clinician‑Directed Injection Kit

Niagen Bioscience (NAGE) closed the trading session on Friday, 23 November 2026, 2.02 % higher than the previous close, with a price of approximately USD 2.52 per share at 11:35 AM Central Europe. The company’s market capitalisation stood at USD 195.4 million, and the volume of shares traded in the past 24 hours was roughly USD 1.3 million. Over the last 200 days the simple moving average has hovered around USD 4.04, while the 52‑week high and low remain at USD 7.95 (5 November 2025) and USD 2.43 (21 October 2026), respectively.

Product Innovation and Initial Clinical Feedback

In its latest announcement, Niagen Bioscience disclosed the launch of a clinician‑directed, prescription‑only liquid injection kit under the Niagen Plus telehealth platform. The kit contains a sterile vial of the company’s patented nicotinamide riboside and is intended for at‑home subcutaneous self‑injection. The new formulation is designed to simplify the administration process and reduce the number of steps required compared with earlier preparations.

Early pilot studies presented in the release report that the injections were well tolerated over a 90‑day period. Participants noted subjective improvements in fatigue, sleep quality, and skin health. In addition, measurable changes were observed in biomarkers related to cellular energy and oxidative stress. Niagen has emphasized that these findings are exploratory and will be validated in larger, controlled trials. The company also highlighted its strategy to scale the platform through telehealth partnerships and a clinician‑prescribed, prescription‑only model that relies on state‑licensed compounding pharmacies for distribution.

Market Context and Peer Performance

During the same 24‑hour window, other companies in the health‑science sector exhibited varied performance:

  • Ses Ai (SES): Down 0.32 %, now trading at USD 0.73 with a market cap of USD 234.4 million.
  • Nu Skin (NUS): Up 3.36 %, trading at USD 4.92 and a market cap of USD 231.7 million. Nu Skin will release its third‑quarter 2026 financial results after market close on 5 November, followed by a conference call and webcast.
  • Galata Acqu Ii (LATA): Up 0.25 %, now at USD 10.22 with a market cap of USD 234.5 million.
  • Bluerock Acquisition (BLRK): Up 0.1 %, trading at USD 10.10 and a market cap of USD 232.3 million.
  • Community /Vt (CMTV): Up 4.83 %, now at USD 43.43, market cap USD 232.1 million, and a price‑to‑earnings ratio of 12.6.

These movements underscore the dynamic nature of the sector, with investors reacting to both product developments and broader market signals.

Company Background

Niagen Bioscience operates under the umbrella of ChromaDex Corporation, a Los Angeles‑based life‑sciences tools and services firm. ChromaDex focuses on research related to nicotinamide adenine dinucleotide (NAD+), a key molecule in healthy aging studies. The company offers services and resources to U.S. customers and is listed on the Nasdaq stock exchange. Further information can be found on the company’s website at www.chromadex.com .

This article provides an overview of Niagen Bioscience’s recent market activity, product announcement, and peer context, presented in a formal and accessible narrative style.